IL10 and lymphoma: We tested if the transcriptional levels of SOCS1 (the only regulator reported in the literature to be associated with inhibition of IL-10 signaling in a lymphoma cell line) (31) and SOCS3 (as control; it does not inhibit IL-10R) were increased by IFN-β treatment.